IP Verse

Methods Of Treating Ocular Conditions - EP3209295

EP3209295

OYSTER POINT PHARMA
Application Number
EP15852340A
Filing Date
Oct 19, 2015
Status
Patent Maintained As Amended
Nov 3, 2023
Grant Date
Dec 6, 2023
External Links
Slate, Register, Google Patents

Bibliography

The patent EP3209295B2 was granted to Oyster Point Pharma on Dec 6, 2023 following the initial filing on Oct 19, 2015 under the application number EP15852340A . The current legal status of the patent is Patent Maintained As Amended.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BECK GREENERSep 9, 2021ADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP1214062
DESCRIPTIONWO2008057938
DESCRIPTIONWO2009111550
DESCRIPTIONWO2010028011
DESCRIPTIONWO2010028033
INTERNATIONAL-SEARCH-REPORTEP1214062
INTERNATIONAL-SEARCH-REPORTUS2011263629
INTERNATIONAL-SEARCH-REPORTUS2012095062
INTERNATIONAL-SEARCH-REPORTUS2012289572
INTERNATIONAL-SEARCH-REPORTWO2004039366
INTERNATIONAL-SEARCH-REPORTWO2013057687
OPPOSITIONEP1214062
OPPOSITIONWO2009069126
SEARCHEP1214062
SEARCHWO2009069126

Non-Patent Literature (NPL) Citations (5) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- A.M. ERVIN et al., "Punctal occlusion for dry eye syndrome", Cochrane Database of Systematic Reviews, (20100908), vol. 2010, no. 9, page CD006775, XP055844655-
OPPOSITION- EUROPEAN MEDICINES AGENCY (EMA), "EPAR summary for the public Champix varenicline", EMA/163166/2014 EMEA/H/C/00699, London, (20140403), pages 1 - 3, URL: https://www.ema.europa.eu/en/documents/overview/champix-epar-summary-public_en.pdf, XP055844659-
OPPOSITION- René Bommer, "Drug Delivery: Nasal Route", René Bommer, J. SWARBRICK, Encyclopedia of Pharmaceutical Technology. 3d ed., USA, Informa Healthcare, (20070000), pages 1201 - 1208, XP055844658-
OPPOSITION- J. PINTOR et al., "Recent developments on dry eye disease treatment compounds", Saudi Journal of Ophthalmology, (20140000), vol. 28, doi:10.1016/j.sjopt.2013.12.003, pages 19 - 30, XP028610374
OPPOSITION- U. GRAU et al., "Next-generation calcineurin inhibitors for ophthalmic indications", Expert Opinion on Investigational Drugs, (20071000), vol. 16, no. 10, pages 1525 - 1540, XP055844660

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents